ClinicalTrials.gg
Status unknownNCT03363425Updated Dec 8, 2017

Effect of Perioperative iv Dexmedetomidine vs. Lidocaine on Postoperative Pain, Analgesic Consumption and Recovery After Abdominal Gynaecological Surgery

A Phase 2/3 interventional study of Lidocaine Iv and Dexmedetomidine in Hysterectomy and Myomectomy, sponsored by University of Athens. Status unknown at 1 site in Greece. Open to female participants aged 30 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-12-08.

Sponsored by University of Athens · Phase 2/3, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Dec 2017), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 2/3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
30 Years to 70 Years
Sex
Female
01

Study summary

Postoperative pain continues to be inadequately managed and is the most common reason for the delay in discharge and unplanned hospital admission after surgery. Opioids remain the mainstay for postoperative analgesia. However, there is a continuous search for adjuvant therapies to reduce the doses of opioids and their related adverse effects, and extend the use of non-opioid analgesia for acute pain after abdominal surgery, thereby improving patient recovery. Currently there are no clinical trials that investigate the effect of intravenous lidocaine vs dexmedetomidine on postoperative pain, analgesic consumption and bowel function of patients undergoing abdominal gynaecological surgery. Purpose of this prospective double blind randomised clinical trial is the investigation of the effect of perioperative intravenous infusion of lidocaine vs dexmedetomidine vs placebo (Normal Saline 0,9%) on analgesic parameters and functional recovery of patients undergoing abdominal gynaecological surgery.

02

Conditions studied

  • Hysterectomy
  • Myomectomy

Browse trials for

Keywords

  • Dexmedetomidine
  • Lidocaine
  • Postoperative Pain
  • Analgesic Consumption
  • Recovery
  • Abdominal Gynaecological Surgery
03

In context

Pain, Postoperative

5,640 studies on the registry are indexed under Pain, Postoperative; 1,230 are open to participants now.

This study's planned enrollment of 60 is below the median of 75 across 4,821 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

University of Athens is the lead sponsor of 139 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women
  • 30-70 years
  • abdominal gynaecological surgery

Exclusion criteria

Exclusion Criteria:

  • patient's refusal
  • to the use of local anesthetics
  • >30 kg/m2
  • history of cardiovascular diseases/ arrhythmias/ conduction abnormalities
  • pregnant women
  • significant renal or hepatic impairment
  • insulin-dependent diabetes mellitus
  • central nervous system disease or psychiatric diseases
  • chronic use of opioids, , clonidine (or other a2 agonist)
  • use of drugs acting on the central nervous system or analgesics during the previous 2 weeks
  • drug/alcohol abuse
  • inability to comprehend the following pain assessment scale
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Lidocaine

    Drug: Lidocaine Iv

  • Active comparator
    Dexmedetomidine

    Drug: Dexmedetomidine

  • Placebo comparator
    Normal Saline 0,9%

    Drug: Normal saline

Interventions

06

What researchers measure

Primary outcomes

  1. analgesic consumption 24 hours postop

    morphine consumption from PCA

    Time frame: 24 hours postoperatively

Secondary outcomes

  1. postoperative pain

    Numeric Pain Rating Scale- NPRS scale (0:no pain 10:worst pain ever)

    Time frame: 0 hours postoperatively

  2. postoperative pain

    Numeric Pain Rating Scale- NPRS scale (0:no pain 10:worst pain ever)

    Time frame: 2 hours postoperatively

  3. postoperative pain

    Numeric Pain Rating Scale- NPRS scale (0:no pain 10:worst pain ever)

    Time frame: 4 hours postoperatively

  4. postoperative pain

    Numeric Pain Rating Scale- NPRS scale (0:no pain 10:worst pain ever)

    Time frame: 8 hours postoperatively

  5. postoperative pain

    Numeric Pain Rating Scale- NPRS scale (0:no pain 10:worst pain ever)

    Time frame: 24 hours postoperatively

  6. postoperative pain

    Numeric Pain Rating Scale- NPRS scale (0:no pain 10:worst pain ever)

    Time frame: 48 hours postoperatively

07

Study locations

1 of 1 sites recruiting
  • Aretaieio University Hospital
    Athens, Greece
    Recruiting
08

References and documents

Publications

  • Rekatsina M, Theodosopoulou P, Staikou C. Perioperative Dexmedetomidine or Lidocaine Infusion for the Prevention of Chronic Postoperative and Neuropathic Pain After Gynecological Surgery: A Randomized, Placebo-Controlled, Double-Blind Study. Pain Ther. 2022 Jun;11(2):529-543. doi: 10.1007/s40122-022-00361-5. Epub 2022 Feb 15. PubMed 35167059 ↗
  • Rekatsina M, Theodosopoulou P, Staikou C. Effects of Intravenous Dexmedetomidine Versus Lidocaine on Postoperative Pain, Analgesic Consumption and Functional Recovery After Abdominal Gynecological Surgery: A Randomized Placebo-controlled Double Blind Study. Pain Physician. 2021 Nov;24(7):E997-E1006. PubMed 34704710 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2017 (actual). Primary completion is estimated for Nov 2018, 12 months after the start.

Of 49 non-industry phase 2/3 interventional studies under Pain, Postoperative, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's planned 12 months is below that.

Counting every sponsor, half of 52 studies reached it within 17 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2017
First posted
Dec 6, 2017
StartActual
Nov 14, 2017
Primary completionEst.
Nov 2018
CompletionEst.
Nov 2018
Last update
Dec 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03363425
Responsible party
Staikou Chryssoula (Assistant Professor of Anaesthesiology, University of Athens) — Principal investigator
First posted
Dec 6, 2017
Start date
Nov 14, 2017
Primary completion
Nov 2018 (estimated)
Completion
Nov 2018 (estimated)
Last update
Dec 8, 2017

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lidocaine · Dexmedetomidine

Start the discussion